Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
230 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (4)

Medical Condition

  • Show all (170)
  • Blood Disorders (1)
  • Cancer (101)
    • Brain Cancer (3)
    • Breast Cancer (13)
    • Gastrointestinal (2)
    • Gynecologic Cancer (30)
    • Kidney Cancer (1)
    • Leukemia (9)
    • Liver Cancer (2)
    • Lung Cancer (4)
    • Lymphoma (10)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (2)
    • (-) Prostate Cancer (3)
    • Sarcoma (2)
    • Skin Cancer (1)
    • Solid Tumors (4)
  • COVID-19 (Coronavirus) (1)
  • Diabetes (2)
  • (-) Ear, Nose and Throat (1)
    • Hearing Loss (1)
  • Endocrine & Metabolic Disease (1)
  • Gastrointestinal and Digestive Diseases (2)
  • Healthy Volunteers (6)
  • Heart Disease (2)
  • Liver Disease (1)
  • Neurological Disorders (3)
  • Obesity (1)
  • Obstetrics & Gynecology (6)
  • Pediatrics (38)
  • Psychiatric Disorders (1)
  • Surgery (1)
  • Transplant (2)
Displaying 1 - 4 of 4

Diffuse Optical Tomography in Prostate Cancer Detection and Risk Stratification - A Pilot Study

Condition: Cancer / Prostate Cancer
Investigator: Emerson Lim, MD
Status: Closed
You are being asked to join this study because you have either been diagnosed with prostate cancer and will be having surgery to remove your prostate or you will be having a prostate biopsy to look for prostate cancer. This study is looking to see if a new imaging device, diffuse optical…
Read More

A study for patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) using study drug JNJ-56021927

Condition: Cancer / Prostate Cancer
Investigator: Edward Gelmann, MD
Status: Closed
The purpose of this study is to compare the clinical benefit (i.e., does it help to improve or slow down the cancer) of adding study drug JNJ-56021927 to combined treatment of abiraterone acetate plus prednisone to treat patients with metastatic Castration-resistant Prostate Cancer (mCRPC). This…
Read More

Study of BMS-986218 Alone or in Combination with Nivolumab for Male Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to assess the effectiveness and safety of combining an investigational drug called BMS-986218 (also known as Anti-CTLA4-NF monoclonal antibody), or BMS-986218 plus nivolumab, with standard of care docetaxel (chemotherapy), in men who have metastatic castration-resistant prostate cancer (mCRPC) that…
Read More

A study to Assess Safety and Effectiveness of Study Drug OTO-104 in Patients at Risk of Hearing Loss From Cisplatin Chemotherapy

Condition: Ear, Nose and Throat / Hearing Loss
Investigator: Alice Lee, MD
Status: Closed
Cisplatin is a chemotherapy medicine that is used to treat a variety of cancers. At high total (cumulative) doses it can be associated with progressive and irreversible hearing loss. The purpose of this study is see if injections of OTO-104 can protect against hearing loss associated with cisplatin therapy in the treatment of…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science